Literature DB >> 20427276

Differential expression of intracellular and secreted osteopontin isoforms by murine macrophages in response to toll-like receptor agonists.

Wei Zhao1, Lijuan Wang, Lei Zhang, Chao Yuan, Paul C Kuo, Chengjiang Gao.   

Abstract

Osteopontin (OPN), expressed by various immune cells, modulates both innate and adaptive immune responses. Different immune cells have shown differential expression of the two isoforms of OPN: secreted form of OPN (sOPN) and intracellular form of OPN (iOPN). However, the molecular mechanisms that control opn gene expression and the OPN isoforms produced by immune cells remain largely unknown. In this study, we demonstrate that OPN mRNA and protein expression are significantly up-regulated upon stimulation with TLR agonists in macrophages. Interestingly, we find that macrophages constitutively express the secreted form of OPN (sOPN), while the intracellular form of OPN (iOPN) is induced following the stimulation with TLR agonists. Phosphoinositide 3-kinase (PI3K), extracellular signal-regulated kinase (ERK), and c-Jun NH(2)-terminal kinase (JNK) that are activated by LPS stimulation were shown to upregulate OPN expression. In addition, chromatin immunoprecipitation (CHIP) assays showed that AP-1 binds to the proximal AP-1 site in the OPN promoter from LPS-stimulated macrophages. Mutation of the AP-1 site in OPN promoter completely ablates LPS-induced OPN promoter activation. Knockdown of c-Jun and c-Fos expression by small interfering RNA (siRNA) significantly decreases LPS-induced OPN expression. Stable cell lines with iOPN overexpression and knockdown showed that TLR-induced iOPN expression is a negative regulator for interferon-beta (IFN-beta) production. Our findings provide new insight into the transcriptional regulation of opn gene and further clarify the isoforms and functions of OPN produced by macrophages.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20427276      PMCID: PMC2898311          DOI: 10.1074/jbc.M110.110312

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  35 in total

1.  The activation state of alphavbeta 3 regulates platelet and lymphocyte adhesion to intact and thrombin-cleaved osteopontin.

Authors:  O Helluin; C Chan; G Vilaire; S Mousa; W F DeGrado; J S Bennett
Journal:  J Biol Chem       Date:  2000-06-16       Impact factor: 5.157

Review 2.  Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodeling, and cell survival.

Authors:  D T Denhardt; M Noda; A W O'Regan; D Pavlin; J S Berman
Journal:  J Clin Invest       Date:  2001-05       Impact factor: 14.808

3.  Eta-1 (osteopontin): an early component of type-1 (cell-mediated) immunity.

Authors:  S Ashkar; G F Weber; V Panoutsakopoulou; M E Sanchirico; M Jansson; S Zawaideh; S R Rittling; D T Denhardt; M J Glimcher; H Cantor
Journal:  Science       Date:  2000-02-04       Impact factor: 47.728

4.  Intracellular osteopontin is an integral component of the CD44-ERM complex involved in cell migration.

Authors:  R Zohar; N Suzuki; K Suzuki; P Arora; M Glogauer; C A McCulloch; J Sodek
Journal:  J Cell Physiol       Date:  2000-07       Impact factor: 6.384

5.  Coupling of osteopontin and its cell surface receptor CD44 to the cell survival response elicited by interleukin-3 or granulocyte-macrophage colony-stimulating factor.

Authors:  Y H Lin; C J Huang; J R Chao; S T Chen; S F Lee; J J Yen; H F Yang-Yen
Journal:  Mol Cell Biol       Date:  2000-04       Impact factor: 4.272

Review 6.  AP-1 in mouse development and tumorigenesis.

Authors:  W Jochum; E Passegué; E F Wagner
Journal:  Oncogene       Date:  2001-04-30       Impact factor: 9.867

7.  The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease.

Authors:  D Chabas; S E Baranzini; D Mitchell; C C Bernard; S R Rittling; D T Denhardt; R A Sobel; C Lock; M Karpuj; R Pedotti; R Heller; J R Oksenberg; L Steinman
Journal:  Science       Date:  2001-11-23       Impact factor: 47.728

8.  The osteopontin-CD44 survival signal involves activation of the phosphatidylinositol 3-kinase/Akt signaling pathway.

Authors:  Y H Lin; H F Yang-Yen
Journal:  J Biol Chem       Date:  2001-10-05       Impact factor: 5.157

9.  Osteopontin promotes integrin activation through outside-in and inside-out mechanisms: OPN-CD44V interaction enhances survival in gastrointestinal cancer cells.

Authors:  Jia-Lin Lee; Mei-Jung Wang; Putty-Reddy Sudhir; Gen-Der Chen; Chin-Wen Chi; Jeou-Yuan Chen
Journal:  Cancer Res       Date:  2007-03-01       Impact factor: 12.701

10.  Osteopontin is involved in the initiation of cutaneous contact hypersensitivity by inducing Langerhans and dendritic cell migration to lymph nodes.

Authors:  J M Weiss; A C Renkl; C S Maier; M Kimmig; L Liaw; T Ahrens; S Kon; M Maeda; H Hotta; T Uede; J C Simon
Journal:  J Exp Med       Date:  2001-11-05       Impact factor: 14.307

View more
  12 in total

1.  Smurf1 protein negatively regulates interferon-γ signaling through promoting STAT1 protein ubiquitination and degradation.

Authors:  Chao Yuan; Jianni Qi; Xueying Zhao; Chengjiang Gao
Journal:  J Biol Chem       Date:  2012-04-02       Impact factor: 5.157

2.  In vitro and in vivo anticancer activity of a synthetic glycolipid as Toll-like receptor 4 (TLR4) activator.

Authors:  Yong-Shiang Lin; Li-De Huang; Chao-Hsiung Lin; Po-Hsiung Huang; Yu-Jen Chen; Fen-Hwa Wong; Chun-Cheng Lin; Shu-Ling Fu
Journal:  J Biol Chem       Date:  2011-09-23       Impact factor: 5.157

3.  NF-κB- and AP-1-mediated DNA looping regulates osteopontin transcription in endotoxin-stimulated murine macrophages.

Authors:  Wei Zhao; Lijuan Wang; Meng Zhang; Peng Wang; Lei Zhang; Chao Yuan; Jianni Qi; Yu Qiao; Paul C Kuo; Chengjiang Gao
Journal:  J Immunol       Date:  2011-01-21       Impact factor: 5.422

4.  Peroxisome proliferator-activated receptor gamma negatively regulates IFN-beta production in Toll-like receptor (TLR) 3- and TLR4-stimulated macrophages by preventing interferon regulatory factor 3 binding to the IFN-beta promoter.

Authors:  Wei Zhao; Lijuan Wang; Meng Zhang; Peng Wang; Lei Zhang; Chao Yuan; Jianni Qi; Yu Qiao; Paul C Kuo; Chengjiang Gao
Journal:  J Biol Chem       Date:  2010-12-10       Impact factor: 5.157

5.  The synthetic cannabinoid R(+)WIN55,212-2 augments interferon-β expression via peroxisome proliferator-activated receptor-α.

Authors:  Eric J Downer; Eileen Clifford; Sylvie Amu; Padraic G Fallon; Paul N Moynagh
Journal:  J Biol Chem       Date:  2012-05-31       Impact factor: 5.157

6.  Reverse right ventricular structural and extracellular matrix remodeling by estrogen in severe pulmonary hypertension.

Authors:  Rangarajan D Nadadur; Soban Umar; Gabriel Wong; Mansour Eghbali; Andrea Iorga; Humann Matori; Rod Partow-Navid; Mansoureh Eghbali
Journal:  J Appl Physiol (1985)       Date:  2012-05-24

7.  Respiratory syncytial virus (RSV) infection in elderly mice results in altered antiviral gene expression and enhanced pathology.

Authors:  Terianne M Wong; Sandhya Boyapalle; Viviana Sampayo; Huy D Nguyen; Raminder Bedi; Siddharth G Kamath; Martin L Moore; Subhra Mohapatra; Shyam S Mohapatra
Journal:  PLoS One       Date:  2014-02-18       Impact factor: 3.240

Review 8.  Osteopontin: A novel regulator at the cross roads of inflammation, obesity and diabetes.

Authors:  Florian Kahles; Hannes M Findeisen; Dennis Bruemmer
Journal:  Mol Metab       Date:  2014-03-22       Impact factor: 7.422

9.  TRIM26 negatively regulates interferon-β production and antiviral response through polyubiquitination and degradation of nuclear IRF3.

Authors:  Peng Wang; Wei Zhao; Kai Zhao; Lei Zhang; Chengjiang Gao
Journal:  PLoS Pathog       Date:  2015-03-12       Impact factor: 6.823

10.  Differential responses of hepatic endoplasmic reticulum stress and inflammation in diet-induced obese rats with high-fat diet rich in lard oil or soybean oil.

Authors:  Min Zhao; Baocai Zang; Mengjie Cheng; Yan Ma; Yanhong Yang; Nianhong Yang
Journal:  PLoS One       Date:  2013-11-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.